BIOCRYST PHARMACEUTICALS, INC. (BCRX) Operating cash flow 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$347.4MFY2025 · since FY2016: -$53.4M → $347.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $347.4M | +767.8% |
| FY2024 | -$52.0M | +45.3% |
| FY2023 | -$95.1M | +41.2% |
| FY2022 | -$161.8M | -13.9% |
| FY2021 | -$142.2M | -5.2% |
| FY2020 | -$135.1M | -50.8% |
| FY2019 | -$89.6M | +3.2% |
| FY2018 | -$92.6M | -125.0% |
| FY2017 | -$41.1M | +23.0% |
| FY2016 | -$53.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice